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E D I T O R I A L C O M M E N TA R Y

Radical Cure: The Case for Anti-Relapse Therapy Against All
Malarias
J. Kevin Baird
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United
Kingdom

(See the article by Douglas et al, on pages 612–620.)

Douglas et al [1] describe patency with
Plasmodium vivax in the 63 days after
treatment of malaria caused by Plasmodium falciparum in .10,000 subjects in
Thailand over a 14-year period who received 25 different therapies. Therapy for
acute malaria aims at the asexual stages
of the organism infecting blood. Among
the many blood schizontocidal drugs
that achieve this therapeutic effect, none
eliminate dormant stages in the liver,
which are known as hypnozoites. Regardless of the species being treated, if
hypnozoites are present, relapse may
occur in the absence of treatment with
primaquine, which is the only registered
hypnozoitocide. The patients evaluated
by Douglas et al [1] did not receive
hypnozoitocidal therapy for the simple
reason that it is not indicated for falciparum malaria. Parasitemia with P.
vivax occurred in 20%–51% of these
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patients, with that rate correlated to the
rapidity of excretion of drugs administered against P. falciparum.
Malaria manifests as many infections
of distinct biological character, with
susceptibility to distinct classes of drugs,
and distinct clinical or epidemiological
consequences [2]. Anopheline mosquitoes transmit all of the 5 species of the
genus Plasmodium known to naturally
infect humans. Each passes through
a series of liver and blood stages of
asexual development that massively
expand the numbers of individual parasites. In a biological sense, that expansion
aims solely at positioning male and female sexual forms (called gametocytes)
where they can access the gut of feeding
anopheline mosquitoes—the only site
where these parasites execute the sexual
recombination essential to their propagation. Humans simply represent
a means for the plasmodia to traffic
among their mosquito definitive hosts.
Two species of plasmodia infecting
humans hedge the probability that biting
anophelines will be present to capitalize
the relatively risky venture into blood.
Among the infectious sporozoites of
P. vivax and Plasmodium ovale introduced
by biting anophelines, an unknown and
variable fraction arrest development after
invading human hepatocytes [3]. These
clinically silent hypnozoites later

commence development and emerge into
the bloodstream to cause another round
of malaria, which is termed a relapse.
The probability, interval, and frequency of relapse in the absence of primaquine treatment vary geographically
in a manner suggesting linkage to a high
probability of a relative abundance of
anophelines [4]. Only 30% of individuals with infection due to P. vivax
from the temperate Korean peninsula,
for example, experience relapse after 8
months and only once; whereas almost
all individuals with infections due to
P. vivax from the perpetually warm and
wet climate of New Guinea experience
relapse within 4 weeks and experience
relapse >5 times. These climate-specific
relapse behaviors persist among strains
transferred to another hemisphere, and
they thus appear to be genetically programmed [3, 4]. In Thailand, 60% of
patients treated for acute vivax malaria with rapidly excreted blood schizontocides experienced relapse within 28
days after patency [5]. When slowly
excreted blood schizontocides (eg,
chloroquine or mefloquine) were applied, no relapses appeared by day 28,
because drug lingering in blood killed
the asexual blood stages emanating
from activated hypnozoites. When drug
levels slip below minimally effective concentrations, relapses may occur [6].
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Figure 1, reprinted from Baird [7], illustrates this principle. The natural relapse
rate after quinine therapy for the primary
attack was 60% at day 28. After chloroquine therapy for the primary attack, relapse did not commence until levels of
drug slipped below the minimally effective concentration at approximately day
35, and the relapse rate reached 50% by
day 63. It would be supposed, therefore,
that delaying relapse would not impact
the broader risks of morbidity and mortality in the community that are incurred
by the failure to administer hypnozoitocidal therapy.
Douglas et al [1] offer a different
view by showing that risk of relapse
diminished significantly when blood
schizontocidal therapy for acute falciparum malaria included a slowly excreted
drug. In other words, the longer-lasting
drugs diminished the burden of blood
infection in the community of treated
patients by eliminating blood stages
derived from hypnozoites. This may be
reconciled to the predominantly experimental challenge data shown in Figure 1
by supposing that natural infection is
associated with more-limited numbers of
hypnozoites and, therefore, is associated
with fewer relapses [8]. Hypnozoites
were effectively killed off by the elimination of their blood stage progeny,
which perhaps represented a significant
proportion of the hypnozoite pool in
such patients.
Although Douglas et al [1] cautiously
put forth the broader advantage to
malaria control gained by applying
slowly excreted therapies, they close with
perhaps a more important point: the
application of primaquine against hypnozoites represents a more complete solution to the significant problem of
relapse. As their data show, the blood
schizontocidal approach to the relapse
problem was only partially effective
(60%; relapse rate, 20% vs 51% with
slowly vs. rapidly excreted therapies,
respectively). Moreover, relapses that
occur after day 63 may deliver similar
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rates of relapse, regardless of the excretion rate of the blood schizontocide.
Among American soldiers infected in the
Pacific theater during World War II, the
median number of relapses was 4.2, and
many of these relapses occurred up to 3
years after exposure [9, 10]. The blood
schizontocidal approach to diminishing relapse rates may be effectively
summarized as ‘‘better than nothing’’
in the current context of therapeutic
paradigms and practice in areas of
endemicity.
Potentially severe hemolytic toxicity
among patients with glucose-6-phosphate
dehydrogenase deficiency (G6PDd)
largely explains the gross underutilization of primaquine by most health
care providers in areas of malaria endemicity. They hesitate to administer
a potentially life-threatening therapy
against an infection that is not supposed
to be threatening to life. The vast majority of practitioners have no access to
the relatively expensive and technically
challenging screening tests for G6PDd.
They cannot know who is at risk for
primaquine toxicity and cannot rationally choose when not to prescribe it.
This is the root of the problem with
unchecked relapse and is the basis of the
appeal of the partial solution provided by

slowly excreted blood schizontocides for
acute malaria.
A very important aspect of the far
broader neglect of vivax malaria is the
failure to develop a simple, inexpensive,
and heat-stable point-of-care diagnostic
tool for G6PDd. This failure impels us to
accept the inability to bring primaquine
to bear against endemic malaria and to
consider partially effective solutions to
the serious problem of relapse. Effective
malaria control, much less successful
elimination, will require a different approach.
Consider a therapeutic paradigm that
includes a rapid diagnostic test (RDT)
for G6PDd that reliably identifies the
minority of people at risk for primaquine
toxicity. Standard primaquine therapy is
administered over a 14-day period as
a means of mitigating risk to patients
with undiagnosed G6PDd. Exposing patients to daily doses of 15–30 mg of primaquine provides opportunity to cease
dosing before serious harm occurs [11].
The peculiar total dose concept with
primaquine—in which delivery of a total
dose of 210–420 mg over 7 days, 14 days,
or even 8 weeks has little bearing upon
efficacy [12]—opens the possibility of
higher dosages over shorter duration
[13]. A reliable RDT for G6PDd would

Figure 1. The graph illustrates cumulative incidence (left axis) of relapse among several hundred
patients infected with Plasmodium vivax from Southeast Asia and the Western Pacific regions and
treated with either rapidly excreted quinine (solid points) or slowly excreted chloroquine (hollow
points). Blood levels of chloroquine and its major metabolite desethylchloroquine (right axis) slowly
decrease to below the minimally effective concentration (MEC) at approximately day 35, coinciding
with commencement of relapse. Reproduced with permission from Baird [7]. Antimicrob Agents
Chemother 2004; 48:4075–83. Copyright American Society for Microbiology.
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enable safer and more-effective treatment against hypnozoites. Such a tool
would also raise the possibility of treating
all patients with malaria, regardless of the
species diagnosed, with anti-relapse
therapy.
The division of prescribed therapies
across species of plasmodia may derive
from practice in zones where malaria
is not endemic. Most patients with
malaria who are seen in that setting (eg,
travelers) likely had a single encounter
with an infected anopheline mosquito
and will usually harbor a single species. In
zones of endemicity, however, patients
have cumulative exposures. If Thailand,
where the disease is endemic, is typical,
then more than half of patients are coinfected with at least 2 species. The people
in any given community in which the
disease is endemic who are demonstrated
to be at risk with 1 species (by diagnosis)
are also at risk for infection by the other
species (whether infection due to that
species is diagnosed or not) [14–16]. It
stands to reason that patients with falciparum malaria in Thailand had a high risk
of co-infection with hypnozoites of P.
vivax, because these sympatric parasites
share the same human and mosquito
hosts. The data reported by Douglas et al
[1] and the data reported by others and
summarized by them should remove
doubt on this important point. Providing therapy that is effective against
P. falciparum but not against P. vivax
is reasonable only when treatment is
hamstrung by the toxicity of primaquine.

Confidence in the safety of primaquine therapy in most patients should
prompt consideration of anti-relapse
therapy after a diagnosis of P. falciparum
malaria in areas in which this species
occurs with P. vivax. This approach
could provide a complete solution to
the problem of relapse in zones of
malaria endemicity. Fielding an RDT
for G6PDd that provides certainty of
primaquine safety could revolutionize
chemotherapeutic strategy and efficacy
in zones of malaria endemicity.
There may be no more important task
than this across the broad array of
work required to control and eliminate
malaria.
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